Orell Mielke
Overview
Explore the profile of Orell Mielke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cuesta H, El Menyawi I, Hubsch A, Hoefferer L, Mielke O, Gabriel S, et al.
Transfusion
. 2022 Aug;
62(9):1894-1907.
PMID: 35916266
Background: Severe hemolysis rarely occurs in patients receiving intravenous immunoglobulin (IVIG) therapy. A systematic review was performed to assess the incidence of IVIG-related hemolysis and the impact of patient and...
2.
Merkies I, van Schaik I, Bril V, Hartung H, Lewis R, Sobue G, et al.
J Peripher Nerv Syst
. 2022 Mar;
27(2):159-165.
PMID: 35266243
Clinical trials in chronic inflammatory demyelinating polyneuropathy (CIDP) often assess efficacy using the ordinal Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. Here, data from the PATH study was reanalyzed...
3.
Alcantara M, Hartung H, Lawo J, Durn B, Mielke O, Bril V
Clin Neurophysiol
. 2021 Jul;
132(9):2184-2190.
PMID: 34293528
Objective: To assess axonal function prior to subcutaneous immunoglobulin (SCIG) therapy or placebo in relation to relapse in chronic inflammatory demyelinating polyneuropathy (CIDP) to determine whether axonal damage can predict...
4.
Tortorici M, Yuraszeck T, Cornblath D, Bril V, Hartung H, Sobue G, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Jun;
10(8):839-850.
PMID: 34085779
The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients...
5.
Bril V, Hartung H, Lawo J, Durn B, Mielke O
Clin Neurophysiol
. 2020 Oct;
132(1):226-231.
PMID: 33039291
Objective: To assess electrophysiology parameters that can reflect patients' clinical status and show changes in nerve function with treatment, in a study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy....
6.
Lewis R, Cornblath D, Hartung H, Sobue G, Lawo J, Mielke O, et al.
J Peripher Nerv Syst
. 2020 Jul;
25(3):230-237.
PMID: 32627277
The Polyneuropathy And Treatment with Hizentra (PATH) study required subjects with chronic inflammatory demyelinating polyneuropathy (CIDP) to show dependency on immunoglobulin G (IgG) and then be restabilized on IgG before...
7.
van Schaik I, Mielke O, Bril V, van Geloven N, Hartung H, Lewis R, et al.
Neurol Neuroimmunol Neuroinflamm
. 2019 Jul;
6(5):e590.
PMID: 31355323
Objective: To investigate the long-term safety and efficacy of weekly subcutaneous IgPro20 (Hizentra, CSL Behring) in chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: In a 48-week open-label prospective extension study to...
8.
Merkies I, van Schaik I, Leger J, Bril V, van Geloven N, Hartung H, et al.
J Peripher Nerv Syst
. 2019 Jan;
24(1):48-55.
PMID: 30672091
Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from...
9.
Mielke O, Bril V, Cornblath D, Lawo J, van Geloven N, Hartung H, et al.
J Peripher Nerv Syst
. 2019 Jan;
24(1):72-79.
PMID: 30672067
In patients with chronic inflammatory demyelinating polyneuropathy (CIDP), intravenous immunoglobulin (IVIG) is recommended to be periodically reduced to assess the need for ongoing therapy. However, little is known about the...
10.
Berger M, Harbo T, Cornblath D, Mielke O
Immunotherapy
. 2018 May;
10(11):919-933.
PMID: 29764262
Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) because it minimizes 'end of cycle' treatment-related fluctuations, reduces systemic adverse effects,...